Drug Discovery · Antwerp, Belgium · Founded 2017 · Privately Held (backing)
Developer of fibrotic disease treatments intended to preserve and restore organ function in fibrotic. AgomAb is based in Antwerp, Belgium and was founded in 2017. Its last known valuation is $416 million. It has raised $334 million across 1 recorded round; the latest was a $101 million Series C in Oct 2023.
Last price · $/share
—
Implied valuation
$415.6M
Total raised
$334.0M
Last round
Later Stage VC (Series C)
Oct 2023
No prints on record
No secondary trades in AgomAb shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of AgomAb with a free account
·The complete investor list: 17 names
·Watch AgomAb: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of AgomAb stock.
